Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors

Lignende værker

• Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials
  af: O’Connor, Jeremy M., et al.
  Udgivet: (2018)
• Factors Associated With Cancer Disparities Among Low-, Medium-, and High-Income US Counties
  af: O’Connor, Jeremy M., et al.
  Udgivet: (2018)
• Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer
  af: Leapman, Michael S., et al.
  Udgivet: (2020)
• Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
  af: Mackiewicz, Jacek, et al.
  Udgivet: (2017)
• Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
  af: Jacek Mackiewicz, et al.
  Udgivet: (2017-03-01)